Searched for
1MG PROFITABILITY
Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tabletsConcord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approv...- World’s hottest market has Korea bulls reaching for protectionSouth Korean stocks are seeing a shift from optimism to caution as investors trim positions and add protection. While chip giants Samsung E...
- World’s hottest market has Korea bulls reaching for protectionSouth Korean stocks are seeing a shift from optimism to caution as investors trim positions and add protection. While chip giants Samsung E...
- Tata 1mg turns Ebitda positive across core units as diagnostics crosses Rs 600 crore in ARRThe company said its diagnostics business crossed an annualised revenue run rate of more than Rs 600 crore during the year, growing over 40...
- Udaan’s pre-IPO top-up; Tata’s Assam chip hub test runHappy Monday! Udaan is in talks to raise fresh funds amid IPO talks. This and more in today's ETtech Morning Dispatch.
- Udaan in talks to raise $50-60 million from existing backers Lightspeed, M&G: sourcesThe Bengaluru-based company had closed a $114 million funding round last June led by the two investors. The new round is being negotiated a...
- NSE launches Electronic Gold Receipts, yet investors prefer ETFs and physical gold; here’s whyAn EGR is a digital certificate backed by actual physical gold stored in a Securities and Exchange Board of India (Sebi)-regulated vault. T...
- Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in CanadaDr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. This marks a significant step for the company in providin...
- India's auto demand to hold steady for 2-3 quarters, but global risks loom over exports, marginsIndia's auto sector is set for continued strong demand for the next 2-3 quarters. Elevated growth is anticipated through CY26. This positiv...
- Tata Digital CEO on company's reset; Groww doubles net profit in Q4Happy Tuesday! Tata Digital CEO Sajith Sivanandan spoke to us exclusively about the ongoing restructuring at the company under him. This an...
- Revamped Tata Neu to bet on loyalty, financial services: Tata Digital CEO Sajith SivanandanTata Digital is pivoting Tata Neu from a broad commerce aggregator to a loyalty-led financial services platform, focusing on payments, inve...
- Jio preps May IPO; Wipro slips after resultsJio Platforms is edging towards a long-awaited IPO as markets wobble amid Iran tensions. This and more in today's ETtech Top 5.
- Air India, Tata Digital losses push Tata Sons’ new ventures towards Rs 29,000 crore hit: ReportTata Sons' new ventures face significant financial challenges. Projections indicate a combined loss of up to Rs 29,000 crore in FY26. Air I...
- Founder exits loom over BigBasket, 1mg as Tata Digital reset continuesBigbasket’s Hari Menon and Vipul Parekh are in the final stages of moving out amid the ongoing CEO search. Meanwhile, Prashant Tandon and G...
- Tata 1mg posts 20% growth in FY25 turnover as it re-enters investment phaseDuring the reporting period, its primary entity Tata 1mg Technologies reported revenue of Rs 375 crore with a threefold jump in profit afte...
- Aurobindo Pharma shares jump 2% after UK arm secures regulatory approval for cancer drugAurobindo Pharma's stock rose after its subsidiary got approval for a cancer drug. CuraTeQ Biologics received the UK's MHRA approval for Be...
- 1mg overtakes PharmEasy in market share in top order changeTata 1mg had a 31% market share in September 2023 against 19% in October 2022 while PharmEasy slipped to 15% from about 33% during the same...
- Tata 1mg will be profitable in a few quarters, says founder Prashant TandonThe company reported a 160% jump in operating revenue to Rs 1,627 crore for the fiscal year ended 2023. However, its net loss more than dou...
- Lupin gains on USFDA approval for Flagyl tabletsPromoters held 46.70 per cent stake in the company as of June 2017.
- Lupin trades higher on getting USFDA nod for pain relief tabletsThe tablets are generic versions of Allergan Sales’ Norco tablets in the same strengths and the product will be launched shortly.
Load More
